Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients

References

• Bradley PJ. Adenoid cystic carcinoma of the head and neck: a review. Curr Opin Otolaryngol Head Neck Surg. 2004;12(2):127–132.
   Google Scholar
• Terhaard CH, Lubsen H, Van der Tweel I, et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck. 2004 August 01;26(8):3.
   Google Scholar
• Howard DJ, Lund VJ. Reflections on the management of adenoid cystic carcinoma of the nasal cavity and paranasal sinuses. Otolaryngol Head Neck Surg. 1985;93(3):338–341.
   Google Scholar
• Laurie SA, Ho AL, Fury MG, et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 2011 August 01;12(8):815–824.
   Google Scholar
• Fordice J, Kershaw C, El-Naggar A, et al. Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg. 1999;125(2):149–152.
   Google Scholar
• Papaspyrou G, Hoch S, Rinaldo A, et al. Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck J Sci Specialties Head Neck. 2011;33(6):905–911.
   Google Scholar
• Licitra L, Marchini SSpinazzè S, et al. Cisplatin in advanced salivary gland carcinoma. A Phase Ii Study Of 25 Patients. Cancer. 1991;68:1874–1877.
   Google Scholar
• Licitra L, Cavina R, Grandi C, et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. . Ann Oncol. 1996 August 01;7(6):640–642.
   Google Scholar
• Debaere D, Vander Poorten V, Nuyts S, et al. Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer. B-ENT. 2011;7(1):1–6.
   Google Scholar
• Wysocki PT, Izumchenko E, Meir J, et al. Adenoid cystic carcinoma: emerging role of translocations and gene fusions. Oncotarget. 2016;7(40):66239.
   Google Scholar
• Pfeffer MR, Talmi Y, Catane R, et al. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol. 2006;43(1):33–36.
   Google Scholar
• Jeng Y, Lin C, Hsu H. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett. 2000;154(1):107–111.
   Google Scholar
• Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a princess margaret hospital phase ii consortium study. J Clin Oncol 2005 Jan 20, 23(3):585–590.
   Google Scholar
• Chae YK, Chung SY, Davis AA, et al. Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. Oncotarget. 2015 Nov;10,;6(35):37117.
   Google Scholar
• Chau NG, Hotte SJ, Chen EX, et al. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol. 2012 Jun 1,;23(6):1562–1570.
   Google Scholar
• Ho AL, Dunn L, Sherman EJ, et al. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. Ann Oncol. 2016 October 01;27(10):1902–1908.
   Google Scholar
• Keam B, Kim SB, Shin SH, et al. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer. 2015 August 01;121(15):2612–2617.
   Google Scholar
• Wong SJ, Karrison T, Hayes DN, et al. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 February 01;27(2):318–323.
   Google Scholar
• Tchekmedyian V, Sherman EJ, Dunn L, et al. Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol. 2019 April 02;JCO1801859.
   Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1,;64(19):7099–7109.
   Google Scholar
• Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005 Feb 10,;23(5):965–972.
   Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11,;356(2):125–134.
   Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24,;359(4):378–390.
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts SJ, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008;45(2):228–247.
   Google Scholar
• Dillon PM, Chakraborty S, Moskaluk CA, et al. Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials. Head Neck. 2016 April 01;38(4):620–627.
   Google Scholar
• Schramm VL, Srodes C, Myers EN. Cisplatin therapy for adenoid cystic carcinoma. Arch Otolaryngol. 1981 December 01;107(12):739–741.
   Google Scholar
• Thomson DJ, Silva P, Denton K, et al. Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Head Neck. 2015 Feb;37(2):182–187.
   Google Scholar
• Locati LD, Perrone F, Cortelazzi B, et al. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: translational analyses and clinical impact. Eur J Cancer. 2016;69:158–165.
   Google Scholar